StockNews.com Upgrades Prestige Consumer Healthcare (NYSE:PBH) to “Buy”

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Wednesday.

A number of other research analysts have also recently issued reports on PBH. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Jefferies Financial Group restated a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Finally, DA Davidson reiterated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.25.

Prestige Consumer Healthcare Trading Down 0.2 %

Prestige Consumer Healthcare stock opened at $78.66 on Wednesday. Prestige Consumer Healthcare has a 12 month low of $57.95 and a 12 month high of $86.36. The stock has a market cap of $3.89 billion, a price-to-earnings ratio of 19.14, a price-to-earnings-growth ratio of 2.32 and a beta of 0.49. The business has a 50 day moving average price of $79.07 and a two-hundred day moving average price of $72.94. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.09. The business had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.07 EPS. As a group, equities analysts forecast that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insider Transactions at Prestige Consumer Healthcare

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now directly owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock valued at $3,187,300 over the last 90 days. 1.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of large investors have recently made changes to their positions in the company. Boston Trust Walden Corp acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter worth $41,785,000. Ariel Investments LLC raised its position in shares of Prestige Consumer Healthcare by 10.7% in the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after buying an additional 274,212 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Prestige Consumer Healthcare by 26.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company’s stock valued at $90,891,000 after buying an additional 272,773 shares during the period. Victory Capital Management Inc. increased its stake in Prestige Consumer Healthcare by 9.0% during the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after acquiring an additional 171,357 shares during the period. Finally, F M Investments LLC bought a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter valued at $11,162,000. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.